Category: Anti-neoplastic
Composition- : Each lyophilized vial contains :- Fludarabin - 50 mg
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
| Specification- | pH: 6.0 7.1 | | Indication : | Fludarabine is primarily indicated in conditions like Chronic lymphocytic leukaemia,Lymphoid malgnancies, and can also be given in adjunctive therapy as an alternative drug of choice in Acute leukemia, Indolent lymphoma, Myclodysplastic syndrome, Myelodysplastic syndrome, Myeloid leukaemia. | | Dosage :- | The recommended adult dose of fludarabine for injection is 25 mg/m² administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5 day course of treatment should commence every 28 days. | | Contra Indications:- | Fludarabine is contraindicated in conditions like Peripheral neuropathy, HIV infection, Renal impairment, Central neuropathy. | | Precautions:- | During and after treatment with fludarabine for injection, vaccination with live vaccines should be avoided. If it is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. | | Drug interaction: | The use of Fludarabin for injection in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity. | | Storage: | Store in refrigerator. Use within 8 hrs if kept at room temperature. |
|
 | |  |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
